SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Neumora Therapeutics Reports Q3 2026 Net Loss of $34.4 Million

Neumora Therapeutics reported a third-quarter 2026 net loss of $34.4 million, compared with $56.8 million a year earlier, and ended September with $85.7 million in cash and cash equivalents. Research and development expenses declined to $22.6 million from $40.5 million. The company said it is not p…

NMRA

Related stories